Most people who come to us for a baseline already know their cholesterol. Fewer know their ApoB. It is the first number we read on every cardiometabolic panel, and the one most often missing from a standard annual check.

The difference is not academic. LDL cholesterol is a mass: how much cholesterol travels inside low density particles in a decilitre of blood. ApoB is a count. Every particle that can enter the artery wall and start a plaque carries exactly one ApoB protein on its surface. Count the protein and you have counted the particles.

Two people can have the same LDL cholesterol and very different particle counts. When each particle carries less cholesterol, you need more of them to reach the same total. That person looks average on a standard lipid panel and carries more risk than the number suggests.

What a standard panel leaves out

A routine lipid panel reports total cholesterol, HDL, triglycerides and LDL cholesterol. In many labs that last figure is not measured at all. It is calculated from the other three with a formula written in 1972, and it drifts most in exactly the people we worry about: anyone with high triglycerides, insulin resistance or a very low LDL after treatment.

ApoB is a direct measurement. One antibody test, run on the same tube of blood, with no fasting needed and a lab error of a few percent. It costs little and most European labs already run it. It is missing from most annual checks out of habit, not because it is hard to get.

Member 0412 is a good example. A runner in her forties, normal weight, no medication. Her standard panel read borderline and her previous doctor suggested waiting a year. Her ApoB told a different story.

Read side by side, the two numbers disagree. LDL cholesterol says watch. ApoB says act. When they disagree, the particle count is the better guide to risk, and that is now the position of the European and Canadian guidelines for anyone with raised triglycerides, diabetes or obesity.

Why the count matters

Plaque does not start because there is cholesterol in the blood. It starts when a particle crosses the inner lining of an artery and gets stuck in the wall. Each crossing is a chance event, so the odds depend on how many particles are trying, not on how much each one carries. More particles, more crossings, more plaque over the years.

Risk follows the number of particles in the blood, not the amount of cholesterol they carry.

This is why two people with the same LDL can face very different futures. Large genetic studies that follow people for decades show the same thing from a different angle: when LDL cholesterol and ApoB point in different directions, heart attacks follow ApoB.

None of this makes LDL cholesterol useless. For most people the two numbers agree, and decades of trials were built on LDL. ApoB simply removes the guesswork in the cases where they do not agree, and those cases are more common than most people expect.

Who should ask for it

Everyone benefits from knowing the number once. For some people it changes the plan more than any other marker on the panel:

1. Anyone with triglycerides above 150 mg/dL, or a waist that has grown faster than their weight.

2. People with type 2 diabetes, prediabetes or a fasting insulin on the high side.

3. Anyone with a parent or sibling who had a heart attack or stroke before 60.

4. People already on a statin, where LDL can look excellent while the particle count stays high.

If you fall in any of those groups and have never seen your ApoB, it is worth asking for at your next blood draw. Measure Lp(a) at the same time. It is largely set by your genes, so one reading in a lifetime is usually enough.

What moves the number

ApoB responds to the same things that move LDL, and it responds in proportion. Less saturated fat and more soluble fibre lower it by a modest amount. Losing visceral fat lowers it further, mostly by bringing triglycerides down. When lifestyle is not enough, a statin, ezetimibe or both will usually bring it into range within a few months.

Member 0412 started with food. Her physician cut saturated fat and added oats and legumes to most days, and she kept her training as it was. Three months in, ApoB had fallen to 96. At that point they agreed on a low dose statin. By month twelve she read 76, under the Kerno target for the first time.

Her LDL cholesterol fell too, from 118 to 84. On its own that would have looked like a good result a few months earlier. Following ApoB kept the treatment going until the particle count, not just the cholesterol, was where it needed to be.

Reading your own result

Lab reports usually flag ApoB only above 130 mg/dL, sometimes 120. That cut off marks the top of the population, and the population is not a healthy reference: most adults in Europe already carry some plaque by fifty. A result inside the lab range can still be higher than you want.

As a rough guide, below 80 mg/dL is where we aim for most members, and below 65 for anyone at higher risk. Between 80 and 100 is worth a conversation and a plan to bring it down. Above 100 we usually act, the way we did for Member 0412. These are starting points for a discussion with your physician, not a diagnosis.

One reading is a snapshot. ApoB moves a little from week to week, with illness, weight change and season. We repeat it at three and twelve months so a decision never rests on a single tube of blood, and we look at the trend alongside triglycerides, fasting insulin and blood pressure.

How we use it at Kerno

ApoB sits on every baseline panel we run and on every follow up. We set a personal target with your physician rather than reading against the lab range, which only tells you how you compare with the general population. For most members that target is below 80 mg/dL. For anyone with diabetes or a strong family history it is lower.

It is one number, and it does not replace the full picture. But it is the clearest single view we have of the process that causes most heart attacks, and it is cheap, quick and repeatable. If you only add one marker to your next blood test, make it this one.